

**Exosome Diagnostics and Therapeutics Market by Type (Diagnostics, Therapeutics), Product & Service (Instruments, Kits, Reagents), Source (Stem Cells, Blood, Blood Plasma, Urine), Application (Cancer, Musculoskeletal, CVD) - Global Forecast to 2032**

Market Report | 2024-06-10 | 251 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The exosome diagnostics market is projected to grow from USD 59 million in 2024 to USD 2,347 million by 2029 at a CAGR of 108.9%. However, the candidates for exosome-based therapeutics are expected to be launched in the market from 2029 onwards. Thus, collectively exosome diagnostics and therapeutics market is expected to generate USD 59 million by 2024 and projected to reach USD 6,848 million in 2032 at a CAGR of 81.2%. Increasing number of clinical trials is expected to support the segment growth. Exosome-based therapies utilize vesicles released by cells to deliver therapeutic payloads. These vesicles offer advantages such as enhanced cargo bioavailability and the ability to cross biological barriers such as the blood-brain barrier. Despite these benefits, exosome therapies have not yet received regulatory approval. This is attributed to the challenges of standardizing exosome isolation and purification methods, scaling production, safety assurance, and regulatory processes. Companies such as Regeneus Ltd (Australia), CUREXSYS (Germany), and Direct Biologics LLC (US) are the key players in this segment that are focused on developing exosome-based therapeutics for clinical indications.

"Instruments & services segment is expected to grow at the fastest pace during the forecast period."

Exosome characterization is done precisely through flow cytometry, nanoparticle tracking analysis, and ultracentrifugation in exosome diagnoses and treatments. The rising demand for exosome characterization & enrichment services is expected to support market growth. Some market players operating in the exosome diagnostics and therapeutics market also use their patented/proprietary technologies to offer end-to-end exosome services, including engineering, characterization, and purification. These players provide support services from a commercial viewpoint, targeted toward scalable exosome manufacturing and analysis from potential diagnostic samples such as blood, urine, and saliva.

"The urine source segment accounted for the largest share in the exosome diagnostics and therapeutics market in 2023."

Rapid commercialization of urine sample-based diagnostic tests is set to drive market. Urinary exosomes, released by cells in the

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

urine system, represent an emerging route for diagnosing and monitoring renal disorders. Their distinct characteristics, such as the capacity to shield their molecular cargo from degradation and contamination, make them primary candidates for renal dysfunction and structural injury biomarkers. The non-invasive method of urine collection and the stability and sufficiency of urinary exosomes highlight its potential for early disease detection and diagnosis.

?

"Cancer is expected to emerge as the dominant application segment in the exosome therapeutics market."

Growing focus on oncology therapeutics is expected to propel the market growth. Exosomes also play a critical role in cancer therapy as carriers of therapeutic cargo, delivering drugs, RNA interference molecules, or immunomodulatory agents to target cancer cells. The University of Texas MD Anderson Cancer Center in Texas (US) is conducting clinical trials (NCT03608631) to study the optimal dosage effects and effects of mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with pancreatic cancer with KrasG12D mutation. Despite these developments, challenges such as optimizing the exosome isolation technology and ensuring efficient delivery of therapeutic cargo to tumors are expected to hinder market growth during the forecast period.

North America dominates the global exosome diagnostics and therapeutics market throughout the forecast period.

The exosome diagnostics and therapeutics market is segmented into four regions: North America, Europe, the Asia Pacific (APAC), and the Rest of the World. As of April 2024, only one exosome-based diagnostic product has been approved and is available in the US. The US has thus emerged as a key revenue source for the global exosome diagnostics and therapeutics market, in turn making North America the dominant region in the market.

Breakdown of supply-side primary interviews by company type, designation, and region:

- By Respondent: Supply Side (70%), Demand side (30%)
- By Designation: C-level (55%), Director-level (20%), and Others (25%)
- By Region: North America (50%), Europe (20%), AsiaPacific (20%), and Rest of the World(10%)

#### List of Companies Profiled in the Report

- Bio-Techne (US)
- NanoFCM Inc. (UK)
- System Biosciences, LLC. (US)
- Capital Biosciences, Inc. (US)
- AMSBIO (UK)
- INOVIQ (Australia)
- Direct Biologics LLC (US)
- Regeneus Ltd (Australia)
- CUREXSYS (Germany)
- Aegle Therapeutics (US)
- Mercy Bioanalytics (US)
- multimmune GmbH (Germany)
- RION (US)
- Exogenus Therapeutics (Portugal)
- Everzom (France)
- Kimera Labs (US)
- NanoSomiX, Inc. (US)
- Exonox Biosciences, Inc. (Taiwan)
- Capricor Therapeutics, Inc. (US)
- Evov Therapeutics (US)
- ILIAS Biologics Inc. (Korea)

#### Research Coverage

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

This report studies the exosome diagnostics and therapeutics market based on type, product & service, source, application, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total exosome diagnostics and therapeutics market. The report forecasts the revenue of the market segments with respect to four major regions.

#### Reasons to Buy the Report:

The report provides insights on the following pointers:

- Market Drivers: The key factors driving the overall market growth emerging potential of exosome-based liquid biopsy, increasing collaborations & commercialization initiatives, and growing outsourcing of exosome manufacturing activities.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the exosome diagnostics and therapeutics market.
- Market Penetration: Comprehensive information on exosome diagnostics and therapeutics offered by the top 21 players in the market. The report analyzes the exosome diagnostics and therapeutics market by type, product & service, application, source, end user, and region.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various products/types of exosome diagnostics and therapeutics across key geographic regions.
- Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the exosome diagnostics and therapeutics market
- Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the exosome diagnostics and therapeutics market

#### Table of Contents:

1□INTRODUCTION□	27
1.1□STUDY OBJECTIVES□	27
1.2□MARKET DEFINITION□	27
1.2.1□INCLUSIONS & EXCLUSIONS□	28
1.3□MARKET SCOPE□	28
1.3.1□MARKETS COVERED□	28
FIGURE 1□MARKET SEGMENTATION□	28
1.3.2□REGIONS COVERED□	29
FIGURE 2□REGIONAL SEGMENTATION□	29
1.3.3□YEARS CONSIDERED□	29
1.3.4□CURRENCY CONSIDERED□	30
1.4□STAKEHOLDERS□	30
1.5□RECESSION IMPACT□	30
2□RESEARCH METHODOLOGY□	31
2.1□RESEARCH DATA□	31
FIGURE 3□RESEARCH DESIGN□	31
2.1.1□SECONDARY DATA□	32
2.1.2□PRIMARY DATA□	32
FIGURE 4□EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: BREAKDOWN OF PRIMARIES□	33
2.2□MARKET ESTIMATION METHODOLOGY□	33
FIGURE 5□EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023□	33

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FIGURE 6	MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023	34
2.2.1	INSIGHTS FROM PRIMARY EXPERTS	35
FIGURE 7	MARKET SIZE VALIDATION FROM PRIMARY SOURCES	35
2.3	MARKET GROWTH RATE PROJECTIONS	37
FIGURE 8	EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET (SUPPLY-SIDE): CAGR PROJECTIONS	37
FIGURE 9	EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	38
2.4	DATA TRIANGULATION AND MARKET BREAKDOWN	39
FIGURE 10	DATA TRIANGULATION METHODOLOGY	39
2.5	RESEARCH ASSUMPTIONS	40
2.6	RISK ASSESSMENT ANALYSIS	40
TABLE 1	EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: RISK IMPACT ANALYSIS	40
?		
2.7	RECESSION IMPACT ANALYSIS	40
TABLE 2	GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)	40
TABLE 3	US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)	41
TABLE 4	US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)	41
3	EXECUTIVE SUMMARY	42
FIGURE 11	EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2029 VS. 2032 (USD MILLION)	42
FIGURE 12	EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY PRODUCT & SERVICE, 2029 VS. 2032 (USD MILLION)	43
FIGURE 13	EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2029 VS. 2032 (USD MILLION)	43
FIGURE 14	EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY APPLICATION, 2029 VS. 2032 (USD MILLION)	44
FIGURE 15	EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2029 VS. 2032 (USD MILLION)	45
FIGURE 16	GEOGRAPHICAL SNAPSHOT OF EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET	46
4	PREMIUM INSIGHTS	47
4.1	EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET OVERVIEW	47
FIGURE 17	EMERGING POTENTIAL OF EXOSOME-BASED LIQUID BIOPSY TO DRIVE MARKET	47
4.2	NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE AND COUNTRY (2029)	48
FIGURE 18	EXOSOME THERAPEUTICS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2029	48
4.3	NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2029 VS. 2032 (USD MILLION)	48
FIGURE 19	EXOSOME DIAGNOSTICS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD	48
5	MARKET OVERVIEW	49
5.1	INTRODUCTION	49
5.2	MARKET DYNAMICS	49
FIGURE 20	EXOSOME DIAGNOSTICS AND THERAPEUTIC MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	49
TABLE 5	EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: IMPACT ANALYSIS	50
5.2.1	DRIVERS	50
5.2.1.1	Emerging potential of exosome-based liquid biopsy	50
5.2.1.2	Increasing initiatives for product commercialization	51
5.2.1.3	Growing outsourcing of exosome-based manufacturing activities	52
5.2.2	RESTRAINTS	52
5.2.2.1	Technical complexities associated with exosome isolation	52
5.2.2.2	Stringent regulatory requirements	53
?		
5.2.3	OPPORTUNITIES	53
5.2.3.1	Growing adoption of exosome biomarkers for personalized medicine	53
5.2.4	CHALLENGES	54

5.2.4.1	Inadequate protocols for exosome development & production	54
5.3	SUPPLY CHAIN ANALYSIS	54
FIGURE 21	EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: SUPPLY CHAIN ANALYSIS	55
5.4	VALUE CHAIN ANALYSIS	56
FIGURE 22	VALUE CHAIN ANALYSIS: MANUFACTURING PROCESSES AND REGULATORY INVESTMENTS ADD MAXIMUM VALUE	56
5.5	PATENT ANALYSIS	57
5.5.1	PATENT ANALYSIS: EXOSOME DIAGNOSTICS	57
FIGURE 23	PATENT APPLICATIONS FOR EXOSOME DIAGNOSTICS, JANUARY 2013-OCTOBER 2023	58
FIGURE 24	PATENT APPLICATIONS FOR EXOSOME DIAGNOSTICS, BY JURISDICTION	58
5.5.2	PATENT ANALYSIS: EXOSOME THERAPEUTICS	59
FIGURE 25	PATENT APPLICATIONS FOR EXOSOME THERAPEUTICS, JANUARY 2013-OCTOBER 2023	59
FIGURE 26	PATENT APPLICATIONS FOR EXOSOME THERAPEUTICS, BY JURISDICTION	60
5.6	REGULATORY LANDSCAPE	60
5.6.1	REGULATORY SCENARIO	60
5.6.1.1	North America	61
5.6.1.1.1	US	61
5.6.1.1.2	Canada	61
5.6.1.2	Europe	62
5.6.1.2.1	Germany	62
5.6.1.2.2	Spain	62
5.6.1.3	Asia Pacific	63
5.6.1.3.1	China	63
5.6.1.3.2	Japan	63
5.6.1.3.3	South Korea	64
5.6.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	64
TABLE 6	LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	64
5.7	PORTER'S FIVE FORCES ANALYSIS	67
TABLE 7	EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: PORTER'S FIVE FORCES ANALYSIS	67
5.7.1	THREAT OF NEW ENTRANTS	67
5.7.2	THREAT OF SUBSTITUTES	67
5.7.3	BARGAINING POWER OF SUPPLIERS	68
5.7.4	BARGAINING POWER OF BUYERS	68
5.7.5	INTENSITY OF COMPETITIVE RIVALRY	68
?		
5.8	KEY STAKEHOLDERS AND BUYING CRITERIA	68
5.8.1	KEY STAKEHOLDERS IN BUYING PROCESS	68
FIGURE 27	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF EXOSOME DIAGNOSTICS & THERAPEUTICS	68
5.8.2	BUYING CRITERIA FOR END USERS	70
FIGURE 28	KEY BUYING CRITERIA FOR END USERS	70
5.9	INVESTMENT AND FUNDING SCENARIO	71
TABLE 8	EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: INVESTMENT & FUNDING SCENARIO	71
5.10	EXOSOME THERAPEUTICS: DEVELOPMENT & MANUFACTURING PROCESS	74
5.10.1	EXOSOME ISOLATION	74
TABLE 9	EXOSOME ISOLATION TECHNIQUES	75
5.10.2	EXOSOME CHARACTERIZATION AND QC	76
5.10.3	EXOSOME PRODUCTION	76
5.11	PIPELINE ANALYSIS	76

FIGURE 29□EXOSOME PIPELINE, BY INTERVENTION TYPE□77

FIGURE 30□EXOSOME PIPELINE, BY PHASE□77

5.11.1□PIPELINE ANALYSIS: EXOSOME THERAPEUTICS□77

FIGURE 31□EXOSOME THERAPEUTICS PIPELINE, BY PHASE□78

FIGURE 32□EXOSOME THERAPEUTICS PIPELINE, BY REGION□78

5.11.2□PIPELINE ANALYSIS: EXOSOME DIAGNOSTICS□78

FIGURE 33□EXOSOME DIAGNOSTIC TESTS PIPELINE, BY APPLICATION□79

FIGURE 34□EXOSOME DIAGNOSTIC TESTS PIPELINE, BY COUNTRY□79

TABLE 10□PIPELINE PRODUCTS FOR EXOSOME DIAGNOSTICS□80

TABLE 11□PIPELINE PRODUCTS FOR EXOSOME THERAPEUTICS□81

5.12□PRICING ANALYSIS□83

5.12.1□AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT□83

TABLE 12□AVERAGE SELLING PRICE OF EXOSOME DIAGNOSTIC PRODUCTS, BY KEY PLAYER□83

5.12.2□AVERAGE SELLING PRICE TREND, BY REGION□83

5.13□ECOSYSTEM ANALYSIS□84

FIGURE 35□EXOSOME DIAGNOSTICS AND THERAPEUTICS: ECOSYSTEM MAP□84

5.14□TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES□85

FIGURE 36□REVENUE SHIFT AND NEW POCKETS□85

5.15□KEY CONFERENCES & EVENTS□86

TABLE 13□EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2024-2025)□86

5.16□TECHNOLOGY ANALYSIS□87

5.16.1□KEY TECHNOLOGIES□87

TABLE 14□EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: KEY TECHNOLOGIES□87

5.16.2□COMPLIMENTARY TECHNOLOGIES□88

5.16.3□ADJACENT TECHNOLOGIES□89

6□EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE□90

6.1□INTRODUCTION□91

TABLE 15□EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)□91

TABLE 16□EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION)□91

6.2□EXOSOME DIAGNOSTICS□91

6.2.1□GROWING FOCUS ON EARLY DISEASE DETECTION & DIAGNOSIS TO PROPEL MARKET□91

TABLE 17□EXOSOME DIAGNOSTICS MARKET, BY REGION, 2022-2029 (USD MILLION)□92

TABLE 18□EXOSOME DIAGNOSTICS MARKET, BY REGION, 2030-2032 (USD MILLION)□92

TABLE 19□NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)□92

TABLE 20□NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2030-2032 (USD MILLION)□93

TABLE 21□EUROPE: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)□93

TABLE 22□EUROPE: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2030-2032 (USD MILLION)□93

TABLE 23□ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)□94

TABLE 24□ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2030-2032 (USD MILLION)□94

6.3□EXOSOME THERAPEUTICS□94

6.3.1□INCREASING NUMBER OF CLINICAL TRIALS TO SUPPORT MARKET GROWTH□94

TABLE 25□EXOSOME THERAPEUTICS MARKET, BY REGION, 2022-2029 (USD MILLION)□95

TABLE 26□EXOSOME THERAPEUTICS MARKET, BY REGION, 2030-2032 (USD MILLION)□95

TABLE 27□NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)□95

TABLE 28□NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2030-2032 (USD MILLION)□96

TABLE 29□EUROPE: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)□96

TABLE 30□EUROPE: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2030-2032 (USD MILLION)□96

TABLE 31	ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	97
TABLE 32	ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2030-2032 (USD MILLION)	97
7	EXOSOME DIAGNOSTICS MARKET, BY PRODUCT & SERVICE	98
7.1	INTRODUCTION	99
TABLE 33	EXOSOME DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)	99
TABLE 34	EXOSOME DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2030-2032 (USD MILLION)	99
?		
7.2	KITS & REAGENTS	99
7.2.1	GROWING DEMAND FOR NON-INVASIVE DIAGNOSTIC KITS TO DRIVE MARKET	99
TABLE 35	EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY REGION, 2022-2029 (USD MILLION)	100
TABLE 36	EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY REGION, 2030-2032 (USD MILLION)	100
TABLE 37	NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2022-2029 (USD MILLION)	100
TABLE 38	NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2030-2032 (USD MILLION)	101
TABLE 39	EUROPE: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2022-2029 (USD MILLION)	101
TABLE 40	EUROPE: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2030-2032 (USD MILLION)	101
TABLE 41	ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2022-2029 (USD MILLION)	102
TABLE 42	ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2030-2032 (USD MILLION)	102
7.3	INSTRUMENTS & SERVICES	103
7.3.1	RIISING FOCUS ON OUTSOURCING EXOSOME PREPARATION ACTIVITIES TO SUPPORT MARKET GROWTH	103
TABLE 43	EXOSOME DIAGNOSTICS MARKET FOR INSTRUMENTS & SERVICES, BY REGION, 2022-2029 (USD MILLION)	103
TABLE 44	EXOSOME DIAGNOSTICS MARKET FOR INSTRUMENTS & SERVICES, BY REGION, 2030-2032 (USD MILLION)	103
8	EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE	104
8.1	INTRODUCTION	105
TABLE 45	EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)	105
TABLE 46	EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION)	105
8.2	STEM CELLS	106
8.2.1	GROWING UPTAKE OF MSC-DERIVED EXOSOMES IN CELLULAR PROCESSES TO DRIVE MARKET	106
TABLE 47	EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY REGION, 2022-2029 (USD MILLION)	106
TABLE 48	EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY REGION, 2030-2032 (USD MILLION)	106
TABLE 49	NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2022-2029 (USD MILLION)	107
TABLE 50	NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2030-2032 (USD MILLION)	107
TABLE 51	EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2022-2029 (USD MILLION)	107
TABLE 52	EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2030-2032 (USD MILLION)	108
TABLE 53	ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2022-2029 (USD MILLION)	108
TABLE 54	ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2030-2032 (USD MILLION)	108
8.3	BLOOD & BLOOD PLASMA	109
8.3.1	ABILITY TO ENHANCE TREATMENT RESPONSE AND DISEASE DIAGNOSIS TO BOOST DEMAND	109
TABLE 55	EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY REGION, 2022-2029 (USD MILLION)	109
TABLE 56	EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY REGION, 2030-2032 (USD MILLION)	109

TABLE 57	NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2022-2029 (USD MILLION)	110
TABLE 58	NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2030-2032 (USD MILLION)	110
TABLE 59	EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2022-2029 (USD MILLION)	110
TABLE 60	EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2030-2032 (USD MILLION)	111
TABLE 61	ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2022-2029 (USD MILLION)	111
TABLE 62	ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2030-2032 (USD MILLION)	111
8.4	URINE	112
8.4.1	RAPID COMMERCIALIZATION OF URINE SAMPLE-BASED DIAGNOSTIC TESTS TO DRIVE MARKET	112
TABLE 63	EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY REGION, 2022-2029 (USD MILLION)	112
TABLE 64	EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY REGION, 2030-2032 (USD MILLION)	112
TABLE 65	NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2022-2029 (USD MILLION)	113
TABLE 66	NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2030-2032 (USD MILLION)	113
TABLE 67	EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2022-2029 (USD MILLION)	113
TABLE 68	EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2030-2032 (USD MILLION)	114
TABLE 69	ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2022-2029 (USD MILLION)	114
TABLE 70	ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2030-2032 (USD MILLION)	114
8.5	OTHER SAMPLES	115
TABLE 71	EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY REGION, 2022-2029 (USD MILLION)	115
TABLE 72	EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY REGION, 2030-2032 (USD MILLION)	115
TABLE 73	NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)	116
TABLE 74	NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2030-2032 (USD MILLION)	116
TABLE 75	EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)	116
TABLE 76	EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2030-2032 (USD MILLION)	117
TABLE 77	ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)	117
TABLE 78	ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2030-2032 (USD MILLION)	117
9	EXOSOME THERAPEUTICS MARKET, BY APPLICATION	118
9.1	INTRODUCTION	119
TABLE 79	EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)	119
TABLE 80	EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)	119
9.2	CANCER	120
9.2.1	GROWING FOCUS ON ONCOLOGY THERAPEUTICS TO PROPEL MARKET	120

TABLE 81	EXOSOME THERAPEUTICS MARKET FOR CANCER, BY REGION, 2022-2029 (USD MILLION)	120
TABLE 82	EXOSOME THERAPEUTICS MARKET FOR CANCER, BY REGION, 2030-2032 (USD MILLION)	121
TABLE 83	NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)	121
TABLE 84	NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2030-2032 (USD MILLION)	121
TABLE 85	EUROPE: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)	122
TABLE 86	EUROPE: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2030-2032 (USD MILLION)	122
TABLE 87	ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)	123
TABLE 88	ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2030-2032 (USD MILLION)	123
9.3	DERMATOLOGICAL DISEASES	124
9.3.1	INCREASING R&D ACTIVITIES FOR WOUND HEALING AND REGENERATIVE MEDICINE TO DRIVE MARKET	124
TABLE 89	EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY REGION, 2022-2029 (USD MILLION)	124
TABLE 90	EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY REGION, 2030-2032 (USD MILLION)	125
TABLE 91	NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)	125
TABLE 92	NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2030-2032 (USD MILLION)	125
TABLE 93	EUROPE: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)	126
TABLE 94	EUROPE: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2030-2032 (USD MILLION)	126
TABLE 95	ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)	127
TABLE 96	ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2030-2032 (USD MILLION)	127
9.4	MUSCULOSKELETAL DISORDERS	127
9.4.1	RISING INCIDENCE OF OSTEOARTHRITIS TO SUPPORT MARKET GROWTH	127
TABLE 97	EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2022-2029 (USD MILLION)	128
TABLE 98	EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2030-2032 (USD MILLION)	129
TABLE 99	NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)	129
TABLE 100	NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2030-2032 (USD MILLION)	129
TABLE 101	EUROPE: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)	130
TABLE 102	EUROPE: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2030-2032 (USD MILLION)	130
TABLE 103	ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)	131
TABLE 104	ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2030-2032 (USD MILLION)	131
9.5	CARDIOVASCULAR DISEASES	132
9.5.1	GROWING FOCUS ON TARGETED THERAPEUTIC DEVELOPMENT TO SUPPORT MARKET GROWTH	132
TABLE 105	EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2029 (USD MILLION)	132
TABLE 106	EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2030-2032 (USD MILLION)	132
TABLE 107	NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)	133
TABLE 108	NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2030-2032 (USD MILLION)	133

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

MILLION) 133

TABLE 109 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 133

TABLE 110 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2030-2032 (USD MILLION) 134

TABLE 111 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 134

TABLE 112 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2030-2032 (USD MILLION) 134

9.6 OTHER APPLICATIONS 135

TABLE 113 EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION) 135

TABLE 114 EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2030-2032 (USD MILLION) 135

TABLE 115 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 136

TABLE 116 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2030-2032 (USD MILLION) 136

TABLE 117 EUROPE: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 136

TABLE 118 EUROPE: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2030-2032 (USD MILLION) 137

TABLE 119 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 137

TABLE 120 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2030-2032 (USD MILLION) 137

10 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER 138

10.1 INTRODUCTION 139

TABLE 121 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION) 139

TABLE 122 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION) 139

10.2 HOSPITALS 139

10.2.1 GROWING COLLABORATIONS WITH PHARMA & BIOPHARMA COMPANIES TO DRIVE MARKET 139

TABLE 123 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2022-2029 (USD MILLION) 140

TABLE 124 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2030-2032 (USD MILLION) 140

TABLE 125 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION) 141

TABLE 126 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2030-2032 (USD MILLION) 141

TABLE 127 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION) 141

TABLE 128 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2030-2032 (USD MILLION) 142

TABLE 129 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION) 142

TABLE 130 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2030-2032 (USD MILLION) 142

10.3 CLINICS AND PHYSICIAN SETTINGS 143

10.3.1 RISING ADOPTION OF LIQUID BIOPSY KITS TO SUPPORT MARKET GROWTH 143

TABLE 131 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY REGION, 2022-2029 (USD MILLION) 143

TABLE 132 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY REGION, 2030-2032

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

(USD MILLION) 143

TABLE 133 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION) 144

TABLE 134 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2030-2032 (USD MILLION) 144

TABLE 135 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION) 144

TABLE 136 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2030-2032 (USD MILLION) 145

TABLE 137 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION) 145

TABLE 138 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2030-2032 (USD MILLION) 145

11 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY REGION 146

11.1 INTRODUCTION 147

TABLE 139 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY REGION, 2022-2029 (USD MILLION) 147

TABLE 140 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY REGION, 2030-2032 (USD MILLION) 147

11.2 NORTH AMERICA 147

11.2.1 NORTH AMERICA: RECESSION IMPACT 148

FIGURE 37 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET SNAPSHOT 148

TABLE 141 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 149

TABLE 142 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2030-2032 (USD MILLION) 149

TABLE 143 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 149

TABLE 144 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION) 150

TABLE 145 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 150

TABLE 146 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION) 150

TABLE 147 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 151

TABLE 148 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION) 151

TABLE 149 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION) 151

TABLE 150 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION) 152

11.2.2 US 152

11.2.2.1 Rising R&D initiatives for development of exosomes to drive market 152

TABLE 151 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 153

TABLE 152 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION) 153

TABLE 153 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 153

TABLE 154 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION) 154

TABLE 155 US: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 154

TABLE 156 US: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION) 154

TABLE 157 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION) 155

TABLE 158 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION) 155

11.2.3 CANADA 155

11.2.3.1 Increasing funding initiatives for genomic-based treatments to support market growth 155

TABLE 159 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 156

TABLE 160 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION) 156

TABLE 161 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 156

TABLE 162 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION) 157

TABLE 163 CANADA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 157

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 164	CANADA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)	157
TABLE 165	CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)	158
TABLE 166	CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION)	158
11.3	EUROPE	158
11.3.1	EUROPE: RECESSION IMPACT	158
FIGURE 38	EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET SNAPSHOT	159
TABLE 167	EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	160
TABLE 168	EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2030-2032 (USD MILLION)	160
TABLE 169	EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)	160
TABLE 170	EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION)	161
TABLE 171	EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)	161
TABLE 172	EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION)	161
TABLE 173	EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)	162
TABLE 174	EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)	162
TABLE 175	EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)	162
TABLE 176	EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION)	163
11.3.2	GERMANY	163
11.3.2.1	Commercialization of pipeline candidates to propel market	163
TABLE 177	GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)	163
TABLE 178	GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION)	163
TABLE 179	GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)	164
TABLE 180	GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION)	164
TABLE 181	GERMANY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)	164
TABLE 182	GERMANY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)	165
TABLE 183	GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)	165
TABLE 184	GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION)	165
11.3.3	UK	166
11.3.3.1	Rising growth in life sciences research to drive market	166
TABLE 185	UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)	166
TABLE 186	UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION)	166
TABLE 187	UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)	167
TABLE 188	UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION)	167
TABLE 189	UK: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)	167
TABLE 190	UK: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)	168
TABLE 191	UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)	168
TABLE 192	UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION)	168
11.3.4	FRANCE	169
11.3.4.1	Presence of emerging players for exosome preparation to fuel market	169
TABLE 193	FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)	169
TABLE 194	FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION)	169
TABLE 195	FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)	169
TABLE 196	FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION)	170
TABLE 197	FRANCE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)	170
TABLE 198	FRANCE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)	170
TABLE 199	FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)	171
TABLE 200	FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION)	171
11.3.5	ITALY	171

#### 11.3.5.1 Rising growth in biotech sector to boost demand 171

TABLE 201 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 172

TABLE 202 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION) 172

TABLE 203 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 172

TABLE 204 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION) 173

TABLE 205 ITALY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 173

TABLE 206 ITALY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION) 173

TABLE 207 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION) 174

TABLE 208 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION) 174

#### 11.3.6 SPAIN 174

##### 11.3.6.1 Increasing initiatives for exosome research to support market growth 174

TABLE 209 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 174

TABLE 210 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION) 175

TABLE 211 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 175

TABLE 212 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION) 175

TABLE 213 SPAIN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 176

TABLE 214 SPAIN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION) 176

TABLE 215 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION) 176

TABLE 216 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION) 177

#### 11.3.7 REST OF EUROPE 177

TABLE 217 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION) 177

TABLE 218 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION) 177

TABLE 219 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 178

TABLE 220 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION) 178

TABLE 221 REST OF EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 178

TABLE 222 REST OF EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION) 179

TABLE 223 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION) 179

TABLE 224 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION) 179

**Exosome Diagnostics and Therapeutics Market by Type (Diagnostics, Therapeutics), Product & Service (Instruments, Kits, Reagents), Source (Stem Cells, Blood, Blood Plasma, Urine), Application (Cancer, Musculoskeletal, CVD) - Global Forecast to 2032**

Market Report | 2024-06-10 | 251 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2025-05-20

Signature

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)